Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

Fan, Kui; Zeng, Li; Guo, Jing; Xie, Shengkun; Yuan, Yu; Chen, Jianwei; Cao, Jin; Xiang, Qinyanqiu; Zhang, Siliang; Luo, Yuanli; Deng, Qingyue; Zhou, Qin; Zhao, Yan; Lu, Hao; Wang, Zhigang; Zhong, Ling

doi:10.7150/thno.53083

Cited by 18 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of ultrasound for the detection of embolism sites is well established in clinical practice. − Ultrasound thrombolysis has been validated in several diseases, including retinal vein occlusion and renal vein thrombosis. Ultrasound-based therapeutic techniques are a promising method to induce effective thrombolysis, mainly through the generation of high negative acoustic pressure (up to 19 MPa) by focused ultrasound . The advantage of ultrasound-based techniques is the rapid lysis of the thrombus and noninvasive revascularization by cavitation.…”

Section: Nanotherapeutics For Ischemic Strokementioning

confidence: 99%

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Liao

Luo

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

Ischemic stroke (IS) is a severe neurological disease caused by the narrowing or occlusion of cerebral blood vessels and is known for high morbidity, disability, and mortality rates. Clinically available treatments of stroke include the surgical removal of the thrombus and thrombolysis with tissue fibrinogen activator. Pharmaceuticals targeting IS are uncommon, and the development of new therapies is hindered by the low bioavailability and stability of many drugs. Nanomedicine provides new opportunities for the development of novel neuroprotective and thrombolytic strategies for the diagnosis and treatment of IS. Numerous nanotherapeutics with different physicochemical properties are currently being developed to facilitate drug delivery by accumulation and controlled release and to improve their restorative properties. In this review, we discuss recent developments in IS therapy, including assisted drug delivery and targeting, neuroprotection through regulation of the neuron environment, and sources of endogenous biomimetic specific targeting. In addition, we discuss the role and neurotoxic effects of inorganic metal nanoparticles in IS therapy. This study provides a theoretical basis for the utilization of nano-IS therapies that may contribute to the development of new strategies for a range of embolic diseases.

show abstract

Section: Nanotherapeutics For Ischemic Strokementioning

confidence: 99%

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Liao

Luo

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Recently, Fan and colleagues synthesized a nano-delivery system capable of targeting podocytes, where its cargo could then be released with the use of ultrasound (controlled-release) [ 65 ]. This nano-delivery system consisted of liposomes with a cargo of perfluoropentane (PFP) and dexamethasone.…”

Section: Renal Clearance Through Interactions With the Gfbmentioning

confidence: 99%

“…This receptor is expressed in high amounts by podocytes. TEM imaging showed that NPs had an average diameter of around 190 nm and could be endocytosed by podocytes in the glomeruli, indicating that they could penetrate the other two layers of the GFB [ 65 ]. It should be noted that nano-delivery systems had penetrated the podocyte layer in mouse models that had been induced with passive Heymann’s nephritis, which simulates leaky glomeruli of patients with membranous nephropathy.…”

Section: Renal Clearance Through Interactions With the Gfbmentioning

confidence: 99%

Atypical Renal Clearance of Nanoparticles Larger Than the Kidney Filtration Threshold

Adhipandito

Cheung

Lin

et al. 2021

IJMS

View full text Add to dashboard Cite

In recent years, several publications reported that nanoparticles larger than the kidney filtration threshold were found intact in the urine after being injected into laboratory mice. This theoretically should not be possible, as it is widely known that the kidneys prevent molecules larger than 6–8 nm from escaping into the urine. This is interesting because it implies that some nanoparticles can overcome the size limit for renal clearance. What kinds of nanoparticles can “bypass” the glomerular filtration barrier and cross into the urine? What physical and chemical characteristics are essential for nanoparticles to have this ability? And what are the biomolecular and cellular mechanisms that are involved? This review attempts to answer those questions and summarize known reports of renal-clearable large nanoparticles.

show abstract

“…Podocytes are epithelial cells that regulate the glomerular filtration barrier, which characterized by actin-rich foot processes that reside on the glomerular basement membrane (GBM) ( Leeuwis et al, 2010 ). The disappearance of podocyte foot processes is a sign of podocyte damage and proteinuric kidney disease, accompanied by changes in podocyte protein expression and reorganization of the actin cytoskeleton ( Fan et al, 2021 ). Panax notoginseng is the main active ingredient of Panax notoginseng (Burkill) F.H.Chen including Ginsenoside, (Rg1, Rg2, Rb1, Rb2, Rb3, Rc, Rd, Re, Rh, F2), Panax notoginosides (R1, R2, R3, R6, Fa, Fc, Fe, R4).…”

Section: Protective Effect Of Panax Ginseng Camey On Renal Innate Cellsmentioning

confidence: 99%

Panax Ginseng C.A.Mey. as Medicine: The Potential Use of Panax Ginseng C.A.Mey. as a Remedy for Kidney Protection from a Pharmacological Perspective

Jin

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Panax ginseng C.A.Mey. has been widely consumed as food/diet supplements from natural sources, and its therapeutic properties have also aroused widespread concern. Therapeutic properties of Panax ginseng C.A.Mey. such as anti-inflammatory, ameliorating chronic inflammation, enhancing the immunity, resisting the oxidation again, and regulating the glucose and lipid metabolism have been widely reported. Recent years, lots of interesting studies have reported the potential use of Panax ginseng C.A.Mey. in the management of DKD. DKD has become the leading cause of end-stage renal disease worldwide, which increases the risk of premature death and poses a serious financial burden. Although DKD is somehow controllable with different drugs such as Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB) and lowering-glucose agents, modern dietary changes associated with DKD have facilitated research to assess the preventive and therapeutic merits of diet supplements from natural sources as medicine including Panax ginseng C.A.Mey. Findings from many scientific evidences have suggested that Panax ginseng C.A.Mey. can relieve the pathological status in cellular and animal models of DKD. Moreover, a few studies showed that alleviation of clinical phenotype such as reducing albuminuria, serum creatinine and renal anemia in DKD patients after application or consumption of Panax ginseng C.A.Mey.. Therefore, this review aims to discuss the effectiveness of Panax ginseng C.A.Mey. as medicine for targeting pathological phenotypes in DKD from a pharmacological perspective. This review will provide new insights into the potential understanding use of Panax ginseng C.A.Mey. in the management of DKD in clinical settings.

show abstract

Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

Cited by 18 publications

References 0 publications

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Atypical Renal Clearance of Nanoparticles Larger Than the Kidney Filtration Threshold

Panax Ginseng C.A.Mey. as Medicine: The Potential Use of Panax Ginseng C.A.Mey. as a Remedy for Kidney Protection from a Pharmacological Perspective

Contact Info

Product

Resources

About